366 related articles for article (PubMed ID: 35812451)
1. Emergence of the CD226 Axis in Cancer Immunotherapy.
Conner M; Hance KW; Yadavilli S; Smothers J; Waight JD
Front Immunol; 2022; 13():914406. PubMed ID: 35812451
[TBL] [Abstract][Full Text] [Related]
2. Hitting the complexity of the TIGIT-CD96-CD112R-CD226 axis for next-generation cancer immunotherapy.
Jin HS; Park Y
BMB Rep; 2021 Jan; 54(1):2-11. PubMed ID: 33298247
[TBL] [Abstract][Full Text] [Related]
3. DNAM-1 and the TIGIT/PVRIG/TACTILE Axis: Novel Immune Checkpoints for Natural Killer Cell-Based Cancer Immunotherapy.
Sanchez-Correa B; Valhondo I; Hassouneh F; Lopez-Sejas N; Pera A; Bergua JM; Arcos MJ; Bañas H; Casas-Avilés I; Durán E; Alonso C; Solana R; Tarazona R
Cancers (Basel); 2019 Jun; 11(6):. PubMed ID: 31234588
[TBL] [Abstract][Full Text] [Related]
4. Poliovirus receptor (PVR)-like protein cosignaling network: new opportunities for cancer immunotherapy.
Wu B; Zhong C; Lang Q; Liang Z; Zhang Y; Zhao X; Yu Y; Zhang H; Xu F; Tian Y
J Exp Clin Cancer Res; 2021 Aug; 40(1):267. PubMed ID: 34433460
[TBL] [Abstract][Full Text] [Related]
5. The CD112R/CD112 axis: a breakthrough in cancer immunotherapy.
Zeng T; Cao Y; Jin T; Tian Y; Dai C; Xu F
J Exp Clin Cancer Res; 2021 Sep; 40(1):285. PubMed ID: 34507594
[TBL] [Abstract][Full Text] [Related]
6. The receptors CD96 and CD226 oppose each other in the regulation of natural killer cell functions.
Chan CJ; Martinet L; Gilfillan S; Souza-Fonseca-Guimaraes F; Chow MT; Town L; Ritchie DS; Colonna M; Andrews DM; Smyth MJ
Nat Immunol; 2014 May; 15(5):431-8. PubMed ID: 24658051
[TBL] [Abstract][Full Text] [Related]
7. TIGIT and CD96: new checkpoint receptor targets for cancer immunotherapy.
Dougall WC; Kurtulus S; Smyth MJ; Anderson AC
Immunol Rev; 2017 Mar; 276(1):112-120. PubMed ID: 28258695
[TBL] [Abstract][Full Text] [Related]
8. Functional characterization of DNAM-1 (CD226) interaction with its ligands PVR (CD155) and nectin-2 (PRR-2/CD112).
Tahara-Hanaoka S; Shibuya K; Onoda Y; Zhang H; Yamazaki S; Miyamoto A; Honda S; Lanier LL; Shibuya A
Int Immunol; 2004 Apr; 16(4):533-8. PubMed ID: 15039383
[TBL] [Abstract][Full Text] [Related]
9. CD96 as a Potential Immune Regulator in Cancers.
Feng S; Isayev O; Werner J; Bazhin AV
Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674817
[TBL] [Abstract][Full Text] [Related]
10. Structural basis for the immune recognition and selectivity of the immune receptor PVRIG for ligand Nectin-2.
Hu S; Han P; Wang M; Cao X; Liu H; Zhang S; Zhang S; Liu J; Han Y; Xiao J; Chen Q; Miao K; Qi J; Tan S; Gao GF; Wang H
Structure; 2024 Apr; ():. PubMed ID: 38626767
[TBL] [Abstract][Full Text] [Related]
11. DNAM-1 control of natural killer cells functions through nectin and nectin-like proteins.
de Andrade LF; Smyth MJ; Martinet L
Immunol Cell Biol; 2014 Mar; 92(3):237-44. PubMed ID: 24343663
[TBL] [Abstract][Full Text] [Related]
12. Interaction between nectin-1 and the human natural killer cell receptor CD96.
Holmes VM; Maluquer de Motes C; Richards PT; Roldan J; Bhargava AK; Orange JS; Krummenacher C
PLoS One; 2019; 14(2):e0212443. PubMed ID: 30759143
[TBL] [Abstract][Full Text] [Related]
13. TIGIT-CD226-PVR axis: advancing immune checkpoint blockade for cancer immunotherapy.
Chiang EY; Mellman I
J Immunother Cancer; 2022 Apr; 10(4):. PubMed ID: 35379739
[TBL] [Abstract][Full Text] [Related]
14. Interaction of PVR/PVRL2 with TIGIT/DNAM-1 as a novel immune checkpoint axis and therapeutic target in cancer.
Stamm H; Wellbrock J; Fiedler W
Mamm Genome; 2018 Dec; 29(11-12):694-702. PubMed ID: 30132062
[TBL] [Abstract][Full Text] [Related]
15. PVRIG and PVRL2 Are Induced in Cancer and Inhibit CD8
Whelan S; Ophir E; Kotturi MF; Levy O; Ganguly S; Leung L; Vaknin I; Kumar S; Dassa L; Hansen K; Bernados D; Murter B; Soni A; Taube JM; Fader AN; Wang TL; Shih IM; White M; Pardoll DM; Liang SC
Cancer Immunol Res; 2019 Feb; 7(2):257-268. PubMed ID: 30659054
[TBL] [Abstract][Full Text] [Related]
16. TIGIT axis: novel immune checkpoints in anti-leukemia immunity.
Qiu D; Liu X; Wang W; Jiang X; Wu X; Zheng J; Zhou K; Kong X; Wu X; Jin Z
Clin Exp Med; 2023 Jun; 23(2):165-174. PubMed ID: 35419661
[TBL] [Abstract][Full Text] [Related]
17. Altered expression of CD226 and CD96 on natural killer cells in patients with pancreatic cancer.
Peng YP; Xi CH; Zhu Y; Yin LD; Wei JS; Zhang JJ; Liu XC; Guo S; Fu Y; Miao Y
Oncotarget; 2016 Oct; 7(41):66586-66594. PubMed ID: 27626490
[TBL] [Abstract][Full Text] [Related]
18. Receptors that interact with nectin and nectin-like proteins in the immunosurveillance and immunotherapy of cancer.
Chan CJ; Andrews DM; Smyth MJ
Curr Opin Immunol; 2012 Apr; 24(2):246-51. PubMed ID: 22285893
[TBL] [Abstract][Full Text] [Related]
19. Molecular Pathways: Targeting CD96 and TIGIT for Cancer Immunotherapy.
Blake SJ; Dougall WC; Miles JJ; Teng MW; Smyth MJ
Clin Cancer Res; 2016 Nov; 22(21):5183-5188. PubMed ID: 27620276
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic Targeting of Checkpoint Receptors within the DNAM1 Axis.
Alteber Z; Kotturi MF; Whelan S; Ganguly S; Weyl E; Pardoll DM; Hunter J; Ophir E
Cancer Discov; 2021 May; 11(5):1040-1051. PubMed ID: 33687987
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
